WIN 57273 is bactericidal for Legionella pneumophila grown in alveolar macrophages
about
In vitro activities of fleroxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumoniaIn vitro activity of Ro 23-9424 against clinical isolates of Legionella speciesIn vitro extracellular and intracellular activities of clavulanic acid and those of piperacillin and ceftriaxone alone and in combination with tazobactam against clinical isolates of Legionella species.Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila-infected and uninfected guinea pigs and their alveolar macrophages.Cooperation between multiple microbial pattern recognition systems is important for host protection against the intracellular pathogen Legionella pneumophila.In vitro activities of gemifloxacin versus five quinolones and two macrolides against 271 Spanish isolates of Legionella pneumophila: influence of charcoal on susceptibility test results.lvgA, a novel Legionella pneumophila virulence factor.Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumoniaComparative postantibacterial activities of pefloxacin, ciprofloxacin, and ofloxacin against intracellular multiplication of Legionella pneumophila serogroup 1In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia.In vitro activity of RP 74501-RP 74502, a novel streptogramin antimicrobial mixture, against clinical isolates of Legionella speciesComparison of charcoal- and starch-based media for testing susceptibilities of Legionella species to macrolides, azalides, and fluoroquinolones.In vitro activity of azithromycin against clinical isolates of Legionella speciesNewly documented antimicrobial activity of quinolones.In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia.In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia.In vitro activity of ABT-773 against Legionella pneumophila, its pharmacokinetics in guinea pigs, and its use to treat guinea pigs with L. pneumophila pneumonia.In vitro intracellular activity and in vivo efficacy of modithromycin, a novel bicyclolide, against Legionella pneumophila.Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia.Intraphagocytic growth induces an antibiotic-resistant phenotype of Legionella pneumophilaRifampin resistance of Legionella pneumophila is not increased during therapy for experimental Legionnaires disease: study of rifampin resistance using a guinea pig model of Legionnaires disease.MyD88-dependent responses involving toll-like receptor 2 are important for protection and clearance of Legionella pneumophila in a mouse model of Legionnaires' disease.Multiple MyD88-dependent responses contribute to pulmonary clearance of Legionella pneumophila.In vitro and intracellular activities of LBM415 (NVP PDF-713) against Legionella pneumophila.Pore formation triggered by Legionella spp. is an Nlrc4 inflammasome-dependent host cell response that precedes pyroptosis.
P2860
Q33744843-AF5DC650-3B9E-467B-8E06-20FE72CFB2FFQ33746330-4FC0C139-316F-405D-8CDE-10043274F721Q33748397-A6AA8DBF-1963-4347-9C66-9122EEF877DAQ33748466-714181B1-395D-4334-9815-C314223BA23BQ33877241-37D032CC-245F-4DF0-9945-8CF9B3D68302Q33980280-449DC7D2-E9DB-42FA-BAE2-04A00FA3D3FCQ34935345-1669693D-EBFC-48BA-984D-4F955F0B7262Q35122254-33A0BA69-7A50-492A-93F4-B3CAF1AC025FQ35272717-5B96229A-541A-4F54-A6E5-84042B063EF0Q35280841-E5331A9C-78F6-4A1A-9CF8-379133A31063Q35812980-90BF8D36-1234-42E4-B1E1-3204CFD1BC16Q36547774-9A9E91BC-17A6-4750-BCA6-C32014C45E7FQ36752693-28D98251-2141-4C45-880A-FA46380ABFA0Q37222571-F579A3F5-FF8A-4CED-BA7C-0866953D232AQ39469546-0F1C3E6B-78C0-4A0C-86C6-2870627F5733Q39477931-19A5338B-F729-4BA6-A30B-E40AB9F80802Q39478420-F853405B-D016-49B4-AD0C-A2FBB471669BQ39609637-49EE72F3-690D-45F0-B705-DD0DF8174A04Q39740470-D2B0F0B8-7D9D-469F-B14D-886FD5832FA0Q39780962-D6121D4C-DF5E-473C-98C8-C7B3CA33DEC1Q40085510-3DBBCE57-D845-47EA-8CD8-3B1A97F36EBDQ41838511-0808BAC9-0DDE-40CF-A13B-A074DDA42A17Q42568936-CB54C54E-3AB0-495F-AC09-4BBA20B068E7Q42839586-1B287783-D2DC-40B3-9AC1-71D98ED5FC81Q42910230-25942B61-F154-429B-A9B1-2F4A5C3775E9
P2860
WIN 57273 is bactericidal for Legionella pneumophila grown in alveolar macrophages
description
1989 nî lūn-bûn
@nan
1989 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
WIN 57273 is bactericidal for Legionella pneumophila grown in alveolar macrophages
@ast
WIN 57273 is bactericidal for Legionella pneumophila grown in alveolar macrophages
@en
type
label
WIN 57273 is bactericidal for Legionella pneumophila grown in alveolar macrophages
@ast
WIN 57273 is bactericidal for Legionella pneumophila grown in alveolar macrophages
@en
prefLabel
WIN 57273 is bactericidal for Legionella pneumophila grown in alveolar macrophages
@ast
WIN 57273 is bactericidal for Legionella pneumophila grown in alveolar macrophages
@en
P2860
P356
P1476
WIN 57273 is bactericidal for Legionella pneumophila grown in alveolar macrophages
@en
P2093
Edelstein MA
Edelstein PH
P2860
P304
P356
10.1128/AAC.33.12.2132
P407
P577
1989-12-01T00:00:00Z